Skip to main content
Fig. 6 | Cancer Nanotechnology

Fig. 6

From: Retro-inversion follicle-stimulating hormone peptide-modified nanoparticles for delivery of PDK2 shRNA against chemoresistant ovarian cancer by switching glycolysis to oxidative phosphorylation

Fig. 6

PDK2 knockdown suppressed tumor growth and peritoneal metastasis of cisplatin-resistant ovarian cancer in vivo. The nude mouse model of cisplatin-resistant peritoneal metastatic ovarian cancer was intraperitoneally injected with cisplatin, DFPP-PDK2 and the combination of cisplatin and DFPP-PDK2 twice a week for 3 weeks. A Representative images of peritoneal tumor foci. B The number of tumor foci at the end point. C The changes of abdominal circumference of the mice. D HE staining in tumor xenografts. Ki67 (E) and Bcl-2 (F) expression via immunohistochemistry in tumor xenografts. (1) control group. (2) cisplatin group. (3) DFPP-PDK2 group. (4) cis + DFPP-PDK2 group. Bars, 50 μm. ***P < 0.001, **P < 0.01, and *P < 0.05

Back to article page